Global X Cybersecurity vs Twist Bioscience Corp — how do they compare? Global X Cybersecurity trades at $42.8, while Twist Bioscience Corp trades at $123.22 (market cap $7.82B). Which is the better fit depends on your goals.
| BUG | TWST | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.00 | $124.88 |
52-Week Low | $23.30 | $24.16 |
Market Cap | — | $7.82B |
Enterprise Value | — | $7.75B |
Signals from Pluang's Aura AI — not financial advice
BUG, the Global X Cybersecurity ETF, trades at $41.68, up 2.36% today and near its 52-week high, with a strong bullish technical signal from moving averages. The ETF has gained significant momentum, rising 82.25% from its 52-week low, as cybersecurity spending forecasts exceed $300 billion in 2026. Recent news highlights sector resilience against AI threats, though key financial ratios like P/E and P/S are not provided in the available data.
The outlook for BUG is positive, driven by robust cybersecurity demand and AI-related security needs, but risks include premium valuations, concentrated US SMID-cap exposure, and potential sector volatility. Analyst sentiment remains bullish with reiterated buy ratings, yet investors should note overbought short-term signals and competitive pressures in the evolving tech landscape.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Trailing returns across standard periods
BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.
Read more on BUG →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →